Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

(Bloomberg) — Stocks lost traction following a furious post-election rally that spurred calls for a breather amid signs of buyer fatigue. Equities fell from near all-time highs, with the S&P 500 ...

Stocks lost steam following a furious post-election rally that spurred calls for a breather amid signs of buyer fatigue.

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

US stock futures edged higher Thursday ahead of a highly-anticipated speech by Fed chair Jerome Powell, which could provide ...